2021 SABCS Onsite Exhibitors
Product Theatre Schedule
Tuesday, December 7, 10:00 am
Cerianna: Seeing Deeper into Recurrent or Metastatic Breast Cancer
presented by GE Healthcare
Tuesday, December 7, 12:00 pm
Explore data for an FDA-approved treatment option in HR+, HER2- breast cancer in certain adjuvant or metastatic settings.PP-AL-US-2989 © Lilly USA, LLC 2021. All rights reserved.
presented by Lilly
Tuesday, December 7, 2:00 pm
Signatera for MRD detection in High-Risk Breast Cancer
presented by Natera
Tuesday, December 7, 4:00 pm
Evolving the Paradigm of Care to Improve Outcomes for Women with ER+ Breast Cancer
presented by Agendia
Wednesday, December 8, 10:00 am
Considerations for Second-Line in HER2+ Metastatic Breast Cancer
presented by Daiichi Sankyo
Wednesday, December 8, 12:00 pm
TUKYSA® (tucatinib): Clinical Trial Data
presented by Seagen
Wednesday, December 8, 2:00 pm
Learn more about an FDA-approved treatment for mTNBC
presented by Gilead Sciences
Wednesday, December 8, 4:00 pm
Advancements in the Prevention of Chemotherapy-Induced Neutropenia: Understanding the Gap and its Managements
presented by BeyondSpring
Thursday, December 9, 10:00 am
Providing the Diagnostics You Need in Breast Cancer Care with One Lab
presented by Neogenomics
Thursday, December 9, 12:00 pm
The Evolving Role of the Oncotype DX® Test in Breast Cancer: TAILORx, RxPONDER, and Beyond
presented by Exact Sciences
Thursday, December 9, 2:00 pm
Clinical/Pathologic Features Are Unrelated to Benefit from Extended Endocrine: Breast Cancer Index is the modern tool for Selecting the right Patients
presented by Biotheranostics, A Hologic Company
Thursday, December 9, 4:00 pm
Resistance to Therapeutic Regimens in MBC: Translating Science to Clinical Decision-making
presented by Sanofi Genzyme
Friday, December 10, 10:00 am
A Treatment Option for Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
presented by Merck
Friday, December 10, 12:00 pm
Expert Perspectives on the Treatment of a Broad Range of Patients With HR+/HER2- Metastatic Breast Cancer
presented by Pfizer Oncology
Friday, December 10, 2:00 pm
A Comprehensive Solution: Somatic and Germline Testing with Artificial Intelligence Capabilities to Inform Treatment Options in Breast Cancer
presented by Tempus
Friday, December 10, 4:00 pm
Recent Developments in Predicting IO Response in TNBC and Other Cancers
presented by Oncocyte
9,572 Symposium attendees + 210 Media + 458 Exhibitors, Non-Exhibiting Sponsors & their Support Staff = 10,240 total attendance. 51% came from 102 countries outside the USA. Click here to view an audited 2021 SABCS registration report, which includes further details.
To request Lead Retrieval, log in to the Sponsorship Portal. Lead Retrieval is under the Sponsorship tab and select item in the drop-down menu.
Code of Conduct
Exhibitors agree to adhere to the compliance guidelines and
codes of conduct governing the interactions of drug and device
manufacturers with healthcare professionals as promulgated by the U.S. Food and Drug Administration, the Department of
Health and Human Services Office of the Inspector General, the
Pharmaceutical Research and Manufacturers of America (PhRMA)
and the Advanced Medical Technology Association AdvaMed.
- Display elements and fixtures cannot exceed a height of ten feet (10’). This rule pertains to both in-line and island displays.
- An individual exhibit cannot straddle an aisle.
- No microphones or vocal amplification may be used at any time.
- Unstaffed exhibits are not permitted.
- Sharing of booth space with an unrelated company is not permitted. “Subleasing” of booth space to an unrelated company is not permitted.
- Table exhibits: exhibit fixtures and product are limited to the table top only.
- All ladders & related equipment must be removed from the building following move-in.
- Departure and/or removal of exhibit prior to end of show will affect placement in subsequent years and may result in exhibitor being barred from exhibiting in the future.
Hours may be subject to change.
Complimentary exhibit area only registrations entitle the registrant to access the virtual exhibit area only. Full registration is required in order to attend SABCS virtual programs.